



RECEIVED

OCT 08 2002

TECH CENTER 1600/2900  
ATTORNEY DOCKET NO. 50062/006001Certificate of Mailing: Date of Deposit: Sept. 27, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Rosemarie Perullo  
Printed name of person mailing correspondence

Rosemarie Perullo  
Signature of person mailing correspondence

OCT 11 2002

RECEIVED

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT - 9 2002

Applicant: Raouf Rekik et al.

Art Unit: 3737

Serial No.: 10/018,235

Examiner:

Filed: December 14, 2001

Customer No.: 21559

Title: NEUROPROTECTIVE AND RETINOPROTECTIVE  
OPHTHAMOLOGIC DRUGS

Assistant Commissioner for Patents  
Washington, DC 20231

TECHNOLOGY CENTER R370C

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office Action on the merits.

RECEIVED  
OCT - 3 2002  
TC 3700 MAIL ROOM

If there are any other charges, or any credits, please apply them to Deposit  
Account No. 03-2095.

Respectfully submitted,

Date:

September 27, 2002

Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) PATENT AND TRADEMARK OFFICE

Attorney Docket No. 50062/006001  
Serial No. 10/018,235  
Applicant Raouf Rekik et al.  
Filing Date December 14, 2001  
Group Not yet assigned  
Customer No. 21559  
IDS Filed September 27, 2002

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

37 CFR §1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
------------------------	---------------	------------	----------	-------	----------	---------------------------------

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/36062	22.07.99	PCT			
	0 158 157 A1	15.03.85	EPO			Yes (partial)
	0 220 107 A2	07.10.86	EPO			
	0 114 333 A2	19.12.83	EPO			


OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Bunning "Inhibition of Angiotensin Converting Enzyme by 2-[N-[(S)-1-carboxy-3-penoxyl-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (HOE 498 Diacid) Comparison with Captopril and Enalaprilat", <i>Arzneim-Forsch./Drug Research</i> , 34;1406-1410; (1984)
	Database WPI Section Ch, Week 199401, "Peptides of Formulae Gly-His-Phe (I) and Tyr-Arg-Pro-Tyr (II) Inhibit Angiotensin I Converting Enzyme (ACE)", <i>Derwent Publication Ltd., London, GB</i> ; Class B03, AN 1994-002154 XP002157734
	Detry-Morel, "Perspectives in the Medical Treatment of Glaucomatous Neuropathy Bases for Neuroprotection", <i>J. Fr. Ophthalmol.</i> , 22(1):122-134; (1999) XP-00087-144 (translation attached)
	Garg et al., "Renal and Retinal Changes after Treatment with Ramipril and Pentoxifyline in Subjects with IDDM", <i>Ann. Ophthalmol.</i> , 30(1):33-37; (1998) XP-000980142
	Shah et al., "Ocular Hypotensive Effect of Ramiprilat in Chronic and Acute Models of Glaucoma in Rabbits", <i>Indian Journal of Pharmacology</i> , 31:110-115; (1999) XP-00980134
	Kulshrestha et al., "Protective Effect of Angiotensin Converting Enzyme Inhibitors in Diabetic Retinopathy", <i>IVOS</i> , 40(4):312; (1999) XP-00980128
	Kusaka-Nakamura et al., "Antihypertensive Treatment in Spontaneously Hypertensive Rats with Streptozotocin-Induced Diabetes Mellitus", <i>Acta Physiol. Hung.</i> 71(2):251-269; (1988) XP-000980228
	Vasmant et al., "Renin-Angioistensin System and A New Converting Enzyme Inhibitor", <i>J. of Cardiovascular Pharmacology</i> 14 (suppl. 4): 546-552; (1989)
	Vogh et al., "Effects of Inhibition of Angiotensin Converting Enzyme and Carbonic Anhydrase on Fluid Production by Ciliary Process, Choroid Plexus, and Pancreas", <i>J. of Ocular Pharmacology</i> 5(4):303-311; (1989) XP-00980132
	Yamagami et al., "Captopril", <i>Dept. of Ophthalmology, Hirosaki Univ. School of Med.</i> , 34:290-297; (1983) XP-000980116

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



TECH CENTER 1600/2900

OCT 0 8 2002

RECEIVED

TECH CENTER 1600/2900

OCT 11 2002

RECEIVED